Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2014 2
2015 1
2016 3
2017 2
2018 2
2019 4
2020 4
2021 2
2022 4
2023 2
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. O'Donoghue ML, et al. Among authors: monsalvo ml. Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29. Circulation. 2022. PMID: 36031810 Clinical Trial.
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. N Engl J Med. 2022. PMID: 36342163 Free article. Clinical Trial.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. Blom DJ, et al. Among authors: monsalvo ml. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29. N Engl J Med. 2014. PMID: 24678979 Free article. Clinical Trial.
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Gaba P, et al. Among authors: monsalvo ml. Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13. Circulation. 2023. PMID: 36779348 Clinical Trial.
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
McClintick DJ, O'Donoghue ML, De Ferrari GM, Ferreira J, Ran X, Im K, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Atar D, Keech A, Giugliano RP, Sabatine MS. McClintick DJ, et al. Among authors: monsalvo ml. J Am Coll Cardiol. 2024 Feb 13;83(6):652-664. doi: 10.1016/j.jacc.2023.11.029. J Am Coll Cardiol. 2024. PMID: 38325990 Free article.
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.
Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, Gouni-Berthold I, Paiva da Silva Lima G, Handelsman Y, Lewis BS, Ohman EM, Wang H, López JAG, Monsalvo ML, Sabatine MS, Leiter LA. Kang YM, et al. Among authors: monsalvo ml. Diabetes Care. 2025 Sep 1;48(9):1512-1516. doi: 10.2337/dc25-0942. Diabetes Care. 2025. PMID: 40544474 Clinical Trial.
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.
Zimerman A, O'Donoghue ML, Ran X, Im K, Ott BR, Mach F, Zavitz K, Kurtz CE, Monsalvo ML, Wang B, Atar D, Keech A, Sabatine MS, Giugliano RP. Zimerman A, et al. Among authors: monsalvo ml. NEJM Evid. 2025 Jan;4(1):EVIDoa2400112. doi: 10.1056/EVIDoa2400112. Epub 2024 Dec 24. NEJM Evid. 2025. PMID: 39718423 Clinical Trial.
Effect of Evolocumab on Lipoprotein Particles.
Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Toth PP, et al. Among authors: monsalvo ml. Am J Cardiol. 2018 Feb 1;121(3):308-314. doi: 10.1016/j.amjcard.2017.10.028. Epub 2017 Nov 8. Am J Cardiol. 2018. PMID: 29221604 Clinical Trial.
29 results